Navigation Links
Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference

98th Annual Meeting of the American Association for Cancer Research (AACR)

TORONTO, April 17, 2007 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") today announced presentation of research on their lead antisense and siRNA compounds at the 98th Annual Meeting of the AACR in Los Angeles, CA, April 14-18, 2007.

The first presentation titled, "Determination of optimized administration schedule of GTI-2040 and docetaxel combination treatment for NSCLC cells in vitro and in vivo," was presented on April 15, 2007.

This research determined a new optimal dosing schedule of GTI-2040 and docetaxel, which resulted in greatly enhanced synergy when docetaxel was given 48 hours after GTI-2040 compared to concomitant administration. This strong synergy was seen in vivo even after a single dose of GTI-2040. The discovery that administration of GTI-2040 prior to docetaxel is associated with this synergy, possibly through a 'stressor' effect due to decreased levels of R2 target expression, may potentially apply to other GTI-2040 combinations as well. This new sequential dose strategy will be an important consideration to maximize efficacy in the GTI-2040 clinical program.

The second presentation titled, "siRNAs targeting the R2 subunit of human ribonucleotide reductase exhibit in vitro and in vivo antitumor activity," will be presented on April 17, 2007.

In this research, Lorus screened a series of siRNAs to select a lead drug candidate, siRNA-1284. siRNA-1284 demonstrated potent antiproliferative and antitumor activity both in vitro and in vivo, coinciding with specific target silencing. These data warrant further development of siRNA-1284 as an anticancer agent. Lorus is also pursuing other cancer targets with its siRNA platform technology to screen and evaluate novel siRNA drug candidates.

"The research announced today provides important supporting data for Lorus' drug development
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:5/19/2008)... May 19 /- Helix Health, the first U....ng a 90-minute webcast this,Wednesday, May 21, 200... Medicine Is Changing the Management of Breast & O...re, http://event.netbriefings.com/event/helixhealt... United States are diagnosed with cancer.,There is...
(Date:5/19/2008)...Be Presented at the 2008 Annual European Congress ...Against Rheumatism (EULAR) -, - Initiation of Pha... of 2008 -, SAN D...iences, Inc.,(Nasdaq: RDEA ) today announced the ...or the treatment of patients with gout, RDEA594. G...
(Date:5/19/2008)...egulatory equivalent filing anticipated in 1Q 2009.../ -- Pharmasset, Inc.,(Nasdaq: VRUS ) has nominat...e treatment of chronic hepatitis C virus (HCV). PS...rase inhibitor of HCV that is being advanced into,...dies required for,submission of an Investigational...
(Date:5/18/2008)...ve Disease Week data highlight effects of AMITIZA ...SAN DIEGO, May 18 /- New study result...ostone) 8 mcg lead to significant relief,of overal...pation (IBS-C).,These results were presented at Di...l international meeting of digestive disease speci...
Breaking Medicine Technology:Join NPR's David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 3Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 4Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 5Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 2Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 3New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 2New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 3New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 4New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 5New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 6New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 7Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control 26 Sexual Function in Women 657 1Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control 26 Sexual Function in Women 657 2Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control 26 Sexual Function in Women 657 3Scientists discover tiny RNAs play a big role in controlling genes 4578 1Food restriction increases dopamine receptor levels in obese rats 4575 1Food restriction increases dopamine receptor levels in obese rats 4575 2Food restriction increases dopamine receptor levels in obese rats 4575 3The new source of islet cells 4571 1
...NCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - Cyto...ta from a Phase 1,dose escalation study evaluating...n) in combination with bortezomib (Velcade(R),Mil...lapsed,multiple myeloma. Data from 33 patients wer...al of Bortezomib (Vel) and Samarium,(Sam) in Multi...
..., Greece--(BUSINESS WIRE)--Jun 28, 2007 - ZIOPHARM...e presentation of two,posters at the XIth Annual I...reece from June 25-28th, 2007. The meeting highlig...atment of multiple,myeloma. ZIOPHARM is presenting...data that further elucidates its unique,mechanism ...
Other Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 2ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 3ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 4
(Date:5/20/2008)...Ambulatory Services of,America, Inc. announced the...t venture to provide outpatient radiation oncology...en Denton Cancer Center, LP and ASA,s,subsidiary, ...of Denton,will own and operate a radiation therapy...ed and operated by Denton Cancer Center., (Logo: ...
(Date:5/20/2008)... out-patient procedures at no c...., May 20 /PRNewswire/ -- Compass Clinical Researc...rancisco Bay Area (RSC) are,hoping to recruit betw...build-up of fluid in the fallopian tubes that can ...part of a study of the effectiveness of a new,out-...
(Date:5/20/2008)...d Fat - and with Omega-3, PARAMUS, N.J., May 20 /...q: SMBL ) has launched Smart Balance(R) Butter Bl...Blend Sticks are 50 percent real butter,and 50 per...lance(R) Butter,Blend Sticks are offered in a conv...ealthier and tasty alternative for use in cooking,...
(Date:5/20/2008)... survival, researchers say. , , TUESDAY...ysis for patients with acute kidney injury does no... the rate of organ failure, a new study finds. ,... in critically ill patients. Approximately 2 perce...ercent of critically ill patients, will suffer fro...
Breaking Medicine News(10 mins):Health News:Ambulatory Services of America, Inc. Announces Joint Venture With Denton Cancer Center, LP 2Health News:Research Grant to Fund Free Surgeries for Women Suffering From Blocked Fallopian Tubes 2Health News:Research Grant to Fund Free Surgeries for Women Suffering From Blocked Fallopian Tubes 3Health News:New Smart Balance(R) Butter Blend Sticks Make Healthier Cooking & Baking Easy 2Health News:More Dialysis Not Better in Acute Kidney Injury 2
... therapy on the medical-surgical wards resulted in...ized management// in patients with diabetic foot u...ossible. “This is the first randomized pilot tr...neous insulin protocol on medical-surgical wards c...
... is present in every part of the body, could be an...at could help// in the development of new treatmen...o the formation of plaques in the brains of patien.... It is also vital for the healthy working of many...
...ed two new devices from Medtronic for children and...EAL-Time Continuous Glucose// Monitoring (CGM) dev...pedi models of the already approved MiniMed Paradi...AL-Time System. Medtronic REAL-Time CGM therapy i...
...ialists at UT Southwestern Medical Center have fou...d bacteria// that cause some of the most common ac...chers have looked for clues to an infection by tra...ing it. But that doesn’t always work because the b...
Other Medicine News:Health News:New Research May Pave the Way for Shorter Hospital Stays for Diabetes Patients 2Health News:New Pediatric Continuous Glucose Monitors Approved 2Health News:‘Fingerprints’ to Track Common Infections in Childr 2Health News:‘Fingerprints’ to Track Common Infections in Childr 3
...ists steerable guidewires across difficult lesions...eter offers a low profile (3F-4F) and is compatibl... crossing difficult occlusions. Once the occlusio...guidewire position and an angioplasty balloon is d...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system.
The new XVG catheter is our highest power thrombectomy catheter designed for accessing distal anatomy. Utilizing proprietary Cross-Stream water jet technology, the XVG catheter removes thrombus quick
...copic navigation system that tracks multiple intra...d Wittkampf, Ph.D., and is being developed by Surg...,The LocaLisa system uses three skin electrode p...art to track catheters. Using a reference electrod...
Medicine Products: